The Street’s Key Stock Analysts Research Reports
$AVGO, $CBS, $ETSY, $MTS, $NBIX, $OBSV, $SEAS, $WMB
Daily HeffX-LTN reviews dozens of the Street’s Key analysts research reports to ID new trading and investing ideas for HeffX-LTN readers. Some reports cover stocks to buy, and others cover stocks to sell or avoid.
Below is a list of the Street’s Key analysts outlook for main issues for Wednesday, as follows:
Broadcom Inc. (NASDAQ:AVGO) was started as Overweight with a 265 price target at Barclays. The consensus target price is 288.45 and the 52-wk trading range is 197.46 – 285.68.
CBS Corp. (NYSE:CBS) was downgraded to Hold from Buy at Argus. The stock trades in a 52-wk range of 47.54 – 67.57, and with a consensus price target at 64.56.
Etsy Inc. (NASDAQ:ETSY) Stifel has maintained it as Hold but raised its target to 46 from 37. KeyBanc Capital Markets reiterated its Overweight rating and raised its target to 51 from 48.
MasTec Inc. (NYSE:MTZ) was raised to Outperform from Neutral by Robert W. Baird.
Neurocrine Biosciences Inc. (NASDAQ:NBIX) was started as Buy and assigned a 137 price target at Stifel.
ObsEva S.A. (NASDAQ:OBSV) was started as Outperform and assigned a 34 price target at Wedbush, which noted that ObsEva is developing some of the 1st and best-in-class drug candidates to improve women’s reproductive health.
SeaWorld Entertainment Inc. (NYSE:SEAS) analysts reiterated as Buy at Stifel but the target price was raised to 35 from 27. Janney maintained its Buy rating but raised its fair value estimate to 31 from 25. Macquarie raised it to Neutral from Underperform.
Williams Companies Inc. (NYSE:WMB) was started as Buy and assigned a 35 price target at Stifel.
Latest posts by Paul Ebeling (see all)
- The Key Reasons for Australia to Exit the Paris Accord Now - January 17, 2019
- Stem Cell Therapy May Be Treatment for Macular Degeneration - January 17, 2019
- Ferrari (NYSE:RACE) Results and Guidance Likely to Surprise - January 17, 2019